LIM Mineralization Protein Gene Delivery for Bone Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stimulating bone formation, such as using bone morphogenetic proteins (BMPs), require large doses, are costly, and can trigger an immune response, while also being susceptible to degradation and limited by receptor availability, necessitating the development of intracellular signaling molecules for more effective and sustainable bone repair and regeneration.
Innovation Solution
Transfecting non-osseous cells, like intervertebral disc cells, with nucleic acids encoding LIM mineralization proteins to stimulate proteoglycan and collagen synthesis, thereby enhancing bone formation and tissue repair without the limitations of extracellular signaling molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bone morphogenetic proteins (BMPs) are used to stimulate bone formation, then bone formation is promoted, but large doses are required, costs increase, and immune responses are triggered
Solution Approach 1:
The patent uses viral vectors (adenovirus, adeno-associated virus) as intermediaries to deliver LIM mineralization protein genes into cells. This mediator approach allows for controlled intracellular production of bone-forming proteins, avoiding the need for large external doses of BMPs while achieving effective bone formation through sustained endogenous protein synthesis
Solution Approach 2:
The invention enables cells to produce their own bone-forming proteins (LIM mineralization proteins) through genetic transfection. The transfected cells autonomously synthesize and secrete the necessary proteins for bone formation, eliminating dependency on external protein administration and reducing the associated dose, cost, and immune response issues
2Reliability
If bone morphogenetic proteins (BMPs) are used to stimulate bone formation, then bone formation is promoted, but production costs increase
Solution Approach 1:
The patent employs genetic engineering to enable target cells to autonomously produce LIM mineralization proteins. This self-service approach eliminates the need for expensive external protein production, purification, and administration, significantly reducing manufacturing costs while maintaining effective bone formation through sustained endogenous protein synthesis
3Reliability
If bone morphogenetic proteins (BMPs) are used to stimulate bone formation, then bone formation is promoted, but receptor availability limits effectiveness
Solution Approach 1:
The patent introduces LIM mineralization protein genes as genetic intermediaries that are directly expressed within cells. This bypasses the need for external BMP-receptor interactions, overcoming receptor availability limitations by enabling intracellular production of bone-forming proteins that act through different or redundant signaling pathways
4Reliability
If extracellular signaling molecules are used for bone repair, then bone formation is stimulated, but the treatment is susceptible to degradation and has limited duration
Solution Approach 1:
The patent enables long-term bone repair by transfecting cells with LIM mineralization protein genes, allowing continuous endogenous production of bone-forming proteins. This self-service mechanism provides sustained therapeutic effect without the degradation issues affecting external protein administration, as the genetic material persists and directs ongoing protein synthesis within the cell
Solution Approach 2:
The invention achieves continuous bone formation stimulation through sustained intracellular expression of LIM mineralization proteins from integrated genetic material. This continuous production mechanism eliminates the intermittent dosing required with extracellular proteins, providing uninterrupted therapeutic action that accelerates and extends bone repair
Data Source
AI summary
Methods of expressing LIM mineralization protein in mammalian cells are described. Methods of expressing LIM mineralization protein and assessing glycosylation of the LIM mineralization protein in prokaryotic and non-mammalian eukaryotic cells are also described. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein. Transfection may be accomplished in vitro, ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid.